Professional
Added to YB: 2025-03-24
Pitch date: 2025-01-07
NVO [bullish]
Novo Nordisk A/S
-55.17%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 81.80
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
growth
Burke Wealth Management Portfolio Holding: Novo Nordisk A/S
NVO (holding update): Shares down on RFK Jr. HHS nomination & Cagri-Sema Phase III results (22.7% weight loss vs 25% target). Still in-line with Zepbound (20%) & better than Wegovy (15%). Obesity market potential huge, supply-constrained. Overreaction to results; Novo remains strong contender in growing GLP-1 market.
Read full article (2 min)